期刊文献+

卵巢浆液性肿瘤中的血管生成研究 被引量:5

Angiogenesis in Serous Ovarian Neoplasms
下载PDF
导出
摘要 目的检测卵巢浆液性肿瘤组织中的血管生成状况。方法采用免疫组化方法检测76例卵巢浆液性肿瘤组织中微血管密度(MVD)并分析其与主要临床病理参数及卵巢癌患者预后的关系。结果在良性、交界性及恶性浆液性卵巢肿瘤组织中MVD值呈逐渐增高趋势,三者之间差异均有显著性;浆液性卵巢癌不同的组织学分级中MVD差异有显著性,分化愈差,MVD值愈高;浆液性卵巢癌不同的FIGO分期中MVD差异有显著性,期别愈晚,MVD值愈高。浆液性卵巢癌组织中MVD值与患者预后有关,微血管密度高者预后差。结论血管生成在浆液性卵巢肿瘤的发生、发展中起重要促进作用,微血管密度值对预测患者预后有一定价值。 Objective To examine the angiogenesis in ovarian serous neoplasms.Methodsmethod was used to examine mieroveasel density (MVD) in 76 cases of serous ovarian neoplasms, and we also investigated MVD of the various histopathologie parameters and investigated the relationship between MVD and the total survival.Results Compared with eystadenomas, the fiasual MVD was signitlcanfly higher in borderline cystadenomas, but signitlcandy lower than cystadenocarcinomas.In serous ovarian carcinoma, the worse of tissual differentiated, the higher of MVD, the difference was significant.There was a signitlcandy higher MVD in the advance carcinomas than the earlier ones.The relationship was defined between MVD and prognosis. Conclusions Angiogenesis is very important in the carcinogenesis and developmentd serous ovarian neoplasams and MVD seems to be valuable prognostic indicator in serous ovarian cystadenocarcinomas.
出处 《医学研究通讯》 2005年第8期16-18,21,共4页 Bulletin of Medical Research
  • 相关文献

参考文献4

  • 1Folkman J, Tumor angiogenesis: Therupeutic implications.N Engl J Med,1971, 285: 1182- 1186.
  • 2Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res, 1986, 46: 467- 473.
  • 3Bmstmann H, Riss P, Naude S, et al.The relevance of angiogenesis in beniga and maligumt epithdial tumors of the ovary: A quantitative histologic study.Gynecol Oncol, 1997, 67: 20- 26.
  • 4汪宏波,王泽华,林美华.交界性和恶性卵巢上皮肿瘤微血管生成的研究[J].实用妇产科杂志,2000,16(6):306-307. 被引量:7

二级参考文献6

  • 1[1]Orre M,Lolfi-miri M,Mamers P,et al. Increased microvessel density in mucinous compared with malignant serous and benign tumors of the ovary. Br J Cancer,1998,77:2204~2209.
  • 2[2]Helen C,Hollingsworth,Elise c,et al. Tumor angiogenesis in advanced stage ovarian carcinomas. Am J Pathol, 1995,147: 33 ~ 41.
  • 3[3]Hermann B, Paul R,Susanna N. The relevance of angiogenesis in benign all malignant epithelial tumors of the ovary: A quantitative histologic study. Gynecol oncol, 1997,67 : 20~ 26.
  • 4[4]Leek R, Kleinerman J,Saidel G, et al. Cytokine networks in solid human tumors:regulation of angiogenesis. J Leuk Biol, 1994, 56:423~426.
  • 5[5]Giampietro G,Emanuela B,Giuseppe V,et al. Prognostic and predictive value of tumor Angiogenesis in ovarian carcinomas. Int J Cancer, 1996,69: 205 ~ 211.
  • 6[6]Gasparini G,Weidner N,Bevilacqua P,et al. Prognostic and predictive value of tumor angiogenesis in ovarian cancer. Iht J Cancer,1996,69:305~311.

共引文献6

同被引文献45

  • 1李文锦,颜士杰,钱和年,张香云,王建六,李小平,宋和存,贾鉴慧,林文玉.卵巢粘液性囊腺癌EGFR、neu、PCNA的表达与临床病理研究[J].浙江肿瘤,1996,2(2):67-69. 被引量:3
  • 2徐建明,李月敏,王岩,赵传华,袁守军,杨武威,李志强,韩宇,AmaliaAzzariti,AngeloParadiso.表皮生长因子受体酪氨酸激酶抑制剂ZD1839与伊利替康联合效应的实验研究[J].中华肿瘤杂志,2006,28(8):578-582. 被引量:4
  • 3刘亚敏,孙江川,常漱芳.卵巢癌的化疗进展[J].重庆医学,2006,35(20):1903-1905. 被引量:6
  • 4张梅娟,张丽华.免疫标记物D2-40在病理诊断中的应用和意义[J].诊断学理论与实践,2007,6(3):277-280. 被引量:20
  • 5Darai E, Bringuier AF, Walker-Combrouze F, et al. CD31 expression in beingn,borderline, and malignant epithelial ovarian tumor: an immunohistochemical and serological analysis. Gynecol Oncol, 1998, 71:122-127.
  • 6Brinkhuis M, Izquierdo MA, Baak JP, et al. Expression of multidmg resistance-associated markers, their relation to quantitative pathologic tumor characteristics and prognosis in advanced ovarian cancer. Anal Cell Pathol, 2002, 24 : 17-23.
  • 7Izquierdo MA, van der Zee AG, Vermorken JB, et al. Drug resistanceassociated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst, 1995, 87 : 1230-1237.
  • 8Arts HJ, Katsaros D, de Vries EG, et al. Drug resistance-asscciated markers P-glycoprotein, muhidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res, 1999, 5:2798-2805.
  • 9Tomov S, Popovska S, Veselinova T, et al. Immunohistoehemical analysis of epidermal growth factor receptors expression in malignant ovarian tumors. Akush Ginekol (Sofiia), 2005,44 Suppl 2:42-47.
  • 10Kolfschoten GM, Hulscher TM, Pinedo HM, et al. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. Br J Cancer, 2000, 83:921-927.

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部